Skromne-Kadlubik G, Hidalgo RR, Ferez AA

Language: Spanish
References: 4
Page: 50-52
PDF size: 409.86 Kb.

ABSTRACT

We labell the molecule of cabergoline with P-32 and tested by radiochromatography, radiopharmacology and genetics in experimental animals with good results. Latelly in 4 cases de pituitary adenoma with hyperprolactinemia we used the radiocabergoline with control of prolactin by radioimmunoassay and SPECT tomography during 8 month, and compared with a homogenous group treated classically with bromocriptyn. The Student t test between both groups gave a statistical result of 0.05 for the radiocabergoline. Because of the encouraging and harmless results obtained by the radiocabergoline in this report, we proposed its use in pituitary adenomas in human being.

REFERENCES

1. Ferrari C. et al., Cabergoline in hiperprolactinemic disorders. J Clin Endrocrinol Metab 1989; 68: 1201.

2. Hutton JT et al. Clinical trial in Parkinson’s disease with cabergoline. Neurology 1996; 46: 1062.

3. Alvarez CJ, Skromne-Kadlubik G. et al. Labell of DDD. J Interna Applied Isotopes 1973; 24: 187.

4. Yalow R, Berson S. Introduction and general consideration in Odellwed, Daughaday WH. Edit. In: Principles of competitive protein binding assays. Philadelphia, USA: J.B. Lippincott Co. Ed. (1991).